Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.
Katie Everson, MS
Advertisement
Articles by Katie Everson, MS
Advertisement
Latest Updated Articles
- Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C–Lowering Therapies
Published: April 13th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
How Can Trauma Affect the Menopausal Transition?
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
